

Atty. Dkt. No. 355901-0104



PCT
X
ew

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BONNAFFE, David et al.


Title: GAMMA-INTERFERON-BINDING COMPOUNDS, PROCESS FOR PREPARING THEM, AND MEDICAMENTS CONTAINING THEM

Appl. No.: 10/518,177

Intl. Filing Date: 6/18/2003

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
Rene Campos	(Printed Name)
 (Signature)	
3 - 02 - 05	
(Date of Deposit)	

TRANSMITTAL

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents for filing in the above-identified application.

1. First Information Disclosure Statement (3 pgs.);
2. PTO Form SB/08 (5 pgs.);
3. Fifty-nine (59) references as cited on Form SB/08 (B1 and C1-C58); and
4. Return postcard.

[X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any

overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date Mar 2 2005

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 251-1105
Facsimile: (650) 856-3710

By Julie L. Heinrich
Julie L. Heinrich
Agent for Applicant
Registration No. 48,070



105-10045 04 MAR 2005

Atty. Dkt. No. 355901-0104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BONNAFFE, David et al.
Title: GAMMA-INTERFERON-BINDING COMPOUNDS, PROCESS FOR PREPARING THEM, AND MEDICAMENTS CONTAINING THEM
Appl. No.: 10/518,177
Int'l. Filing Date: 6/18/2003
Date:
Examiner: Not Yet Assigned
Art Unit: Not Yet Assigned

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
<i>Rene Campos</i> (Printed Name)	
<i>R C</i> (Signature)	
3 - 02 - 05 (Date of Deposit)	

FIRST INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

The relevance of the foreign-language document is described in the English Abstract provided in the PCT publication. An English translation of the foreign-language document is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date

Mar 2 2005

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 251-1105
Facsimile: (650) 856-3710

By

Julie L Heinrich

Julie L Heinrich
Agent for Applicant
Registration No. 48,070

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 2, 2005 <i>Please use as many sheets as necessary)</i>				Complete if Known		
Sheet		1	of	5	Attorney Docket Number	355901-0104
					Application Number	10/518,177
					Int'l Filing Date	6/18/2003
					First Named Inventor	David BONNAFFE
					Group Art Unit	Not Yet Assigned
					Examiner Name	Not Yet Assigned

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	Lortat-Jacob et al. "Interferon-Gamma Binds to Heparan Sulfate by a Cluster of Amino Acids Located in the C-terminal Part of the Molecule" <i>FEBS LETTERS</i> 280(1):152-154 (1991)	
	C2	Lortat-Jacob et al. "Non-receptor-Mediated Tissue Localization of Human Interferon-Gamma. Role of Heparan Sulfate/Heparin-Like Molecules" <i>Cytokine</i> 8(7):557-566 (1996)	
	C3	Billiau, Alfons "Interferon-Gamma: Biology and Role in Pathogenesis" <i>Advances in Immunol.</i> 62:61-130 (1996)	
	C4	Boutin et al. "Intrapleural Treatment with Recombinant Gamma-Interferon in Early Stage Malignant Pleural Mesothelioma" <i>Cancer</i> 74:2460-2467 (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10 Rec'd PTO 04 MAR 2005

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">O I P E J C MAR 04 2005 INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 2, 2005 (use as many sheets as necessary)</p> <p style="text-align: center;">INTERFEE SHEET TRADEMARK OFFICE</p> <p style="text-align: center;">2 of 5</p>				Complete if Known	
				Application Number	10/518,177
				Int'l Filing Date	6/18/2003
				First Named Inventor	David BONNAFFE
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	355901-0104

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C5	Escudier et al. "Combination of Interleukin-2 and Gamma Interferon in Metastatic renal Cell Carcinoma" <i>Eur. J. Cancer</i> 29A(5):724-728 (1993)	
	C6	Jett et al. "Phase III Trial of Recombinant Interferon Gamma in Complete Responders with Small-Cell Lung Cancer" <i>J. Clin. Oncol.</i> 12(11):2321-2326 (1994)	
	C7	Gallin, et al. "A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease" <i>New Engl. J. Med.</i> 324(8) 509-516 (1991)	
	C8	Cannon et al. "Prospective 5-Year Followup of Recombinant Interferon-Gamma in Rheumatoid Arthritis" <i>J. Rheumatol.</i> 20:1867-1873 (1993)	
	C9	Czarniecki et al. "Interferon-Gamma and Resistance to Bacterial Infections" <i>APMIS</i> 101:1-17 (1993)	
	C10	Murray et al. "Interferon-Gamma and Host Antimicrobial Defense: Current and Future Clinical Applications" <i>Am. J. Med.</i> 97:459-467 (1994)	
	C11	Kakumu et al. "Treatment with Human Gamma Interferon of Chronic Hepatitis B: Comparative Study with Alpha Interferon" <i>J. Med. Virol.</i> 35:32-37 (1991)	
	C12	Freundlich et al. "Treatment of Systemic Sclerosis with Recombinant Interferon-Gamma" <i>Arthritis Rheum.</i> 35(10):1134-1142 (1992)	
	C13	Todd et al. "Interferon Gamma-1b" <i>Drugs</i> 43(1):111-122 (1992)	
	C14	Froyen et al. "Potential Therapeutic Use of Antibodies Directed Towards HIFN-Gamma" <i>Biotherapy</i> 10:49-57 (1997)	
	C15	Ozmen et al. "Soluble Interferon-Gamma Receptor: A Therapeutically Useful Drug for Systemic Lupus Erythematosus" <i>J. of Interferon Res.</i> 14:283-284 (1994)	
	C16	Ozmen et al. "Experimental Therapy of Systemic Lupus Erythematosus: The Treatment of NZB/W Mice with Mouse Soluble Interferon-Gamma Receptor Inhibits the Onset of Glomerulonephritis" <i>Eur. J. Immunol.</i> 25:6-12 (1995)	
	C17	Lortat-Jacob et al. "High-Affinity Binding of Interferon-Gamma to a basement Membrane Complex (Matrigel)" <i>J. Clin. Invest.</i> 87:878-883 (1991)	
	C18	Lortat-Jacob et al. "Interferon-Gamma C-Terminal Function: New Working Hypothesis. Heparan Sulfate and Heparin, New Targets for IFN-Gamma, Protect, Relax The Cytokine and Regulate Its Activity" <i>Cell. Mol. Biol.</i> 37(3):253-260 (1991)	
	C19	Lortat-Jacob et al. "Heparin Decreases the Blood Clearance of Interferon-Gamma and Increases its Activity by Limiting the Processing of its Carboxyl-terminal Sequence" <i>J. of Biol. Chem.</i> 271(27):16139-16143 (1996)	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">O I P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>MAR 04 2005 Date Submitted: March 2, 2005 (use as many sheets as necessary)</small> <small>PATENT & TRADEMARK OFFICE SHEET 3 OF 5</small></p>			Complete if Known	
			Application Number	10/518,177
			Int'l Filing Date	6/18/2003
			First Named Inventor	David BONNAFFE
			Group Art Unit	Not Yet Assigned
			Examiner Name	Not Yet Assigned
			Attorney Docket Number	355901-0104

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C20	Halme et al. "Inhaled Recombinant Interferon Gamma in Patients with Lung Cancer: Pharmacokinetics and Effects on Chemiluminescence Responses of Alveolar Macrophages and Peripheral Blood Neutrophils and Monocytes" <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 31(1):93-101 (1995)	
	C21	Lack et al. "Nebulized INFN-Gamma Inhibits the Development of Secondary Allergic Responses in Mice" <i>J. Immunol.</i> 157:1432-1439 (1996)	
	C22	Short et al. "Percutaneous Absorption of Biologically-Active Interferon-gamma in a Human Skin Graft-Nude Mouse Model" <i>Pharm. Res.</i> 13(7):1020-1027 (1996)	
	C23	Lortat-Jacob et al. "Molecular Organization of the Interferon Gamma-Binding Domain in Heparan Sulphate" <i>Biochem. J.</i> 310:497-505 (1995)	
	C24	Lee, et al. "Synthesis of 3-(2-Aminoethylthio)Propyl Glycosides" <i>Carbohydrate Res.</i> 37:193-201 (1974)	
	C25	Schmidt et al. "New Methods for the Synthesis of Glycosides and Oligosaccharides – Are There Alternatives to the Koenigs-Knorr Method?" <i>Agnew Chem. Int. Ed. Engl.</i> 25:212-235 (1986)	
	C26	Klotz et al. "Anomeric O-Alkylation of O-Unprotected Hexoses and Pentoses – Convenient Synthesis of Decyl, Benzyl, and Allyl Glycosides" <i>Liebigs. Ann. Chem.</i> 683-690 (1993)	
	C27	Klotz et al. "Anomeric O-Alkylation of O-Acetyl-Protected Sugars" <i>J. Carbohydrate Chemistry</i> 13(8):1093-1101 (1994)	
	C28	Terjung et al. "New 2/2-Type Surfactants Via Anomeric O-Alkylation of Mannofuranose" <i>Carbohydr. Res.</i> 297:229-242 (1997)	
	C29	Lubineau et al. "Syntheses of α -Linked Derivatives of N-Acetyl Glucosamine and Gal- β (1-3)GalNAc (T Antigen) Directly with the Natural N-Acetyl Protecting Group" <i>J. Chem. Soc. Chem. Commun.</i> 1918-1919 (1989)	
	C30	Lubineau et al. "Stereoselectivity Control in Anomeric O-Alkylation. Application to the Synthesis of C ₂ Symmetric Glycoconjugates" <i>Tetrahedron Letters</i> 38(23):4087-4090 (1997)	
	C31	Sakai et al. "Synthesis of a Conformationally Constrained Heparin-Like Pentasaccharide" <i>Chem. Eur. J.</i> 2(8):1007-1013 (1996)	
	C32	Petitou et al. "A Synthetic Heparin/Heparan Sulfate-Like Decasaccharide Releases Lipase Activity <i>In Vivo</i> . Chemical Synthesis and Biological Activity" <i>Bioorg. Med. Chem. Lett.</i> 7(15):2067-2070 (1997)	
	C33	Petitou et al. "First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin" <i>Agnew. Chem. Int. Ed.</i> 37(21):3009-3014	
	C34	Lei et al. "Synthesis of a 3-Deoxy-L-Iduronic Acid Containing Heparin Pentasaccharide to Probe the Conformation of the Antithrombin III Binding Sequence" <i>Boorgan. & Med. Chem.</i> 6:1337-1346 (1998)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

04 MAR 2005

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

O I P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT MAR 04 2005 Date Submitted: March 2, 2005 (use as many sheets as necessary)			Complete if Known		
			Application Number	10/518,177	
			Int'l Filing Date	6/18/2003	
			First Named Inventor	David BONNAFFE	
			Group Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
			Attorney Docket Number	355901-0104	
4 of 5					

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	C35	Basten et al. "In Vitro Evaluation of Synthetic Heparin-Like Conjugates Comprising different Thrombin Binding Domains" <i>Bioorg. Med. Chem. Lett.</i> 8:1201-1206 (1998)		
	C36	Duchaussoy et al. "Identification of a Hexasaccharide Sequence Able to Inhibit Thrombin and Suitable for 'Polymerisation'" <i>Carbo. Res.</i> 317:63-84 (1999)		
	C37	Duchaussoy et al. "Assessment Through Chemical Synthesis of the Size of the Heparin Sequence Involved in Thrombin Inhibition" <i>Carbo. Res.</i> 317:85-99 (1999)		
	C38	Koshida et al. "Synthesis of Heparin Partial Structures and their Binding Activities to Plateletes" <i>Bioor. Med. Chem. Lett.</i> 9:3127-3132 (1999)		
	C39	Kovensky et al. "A Synthetic Heparin Sulfate Pentasaccharide, Exclusively Containing L-Iduronic Acid, Displays Higher Affinity for FGF-2 than its D-Glucuronic Acid-Containing Isomers" <i>Bioor. & Med. Chem.</i> 7:1567-1580 (1999)		
	C40	La Ferla et al. "Synthesis of Disaccharide Sub-Units of a New Series of Heparin Related Oligosaccharides" <i>Tetrahedron</i> 55:9867-9880 (1999)		
	C41	Lubineau et al. "New Accesses to L-Iduronyl Synthons" <i>Tetrahedron Lett.</i> 41:307-311 (2000)		
	C42	Macher et al. "Synthesis of L-Idofuranuro-6,3-Lactone and Its Derivatives via Hexodialdofuranoses" <i>Carbo. Res.</i> 80:45-51 (1980)		
	C43	Jacquinet et al. "Synthesis of Heparin Fragments. A Chemical Synthesis of the Trisaccharide o-(2-Deoxy-2-Sulfamido-3,6-Di-O-Sulfo- α -D-Glucopyranosyl), etc." <i>Carbo. Res.</i> 130:221-241 (1984)		
	C44	Baggett et al. "Re-examination of the acid hydrolysis of 5,6-Anhydro-1,2-O-Isopropylidene- β -L-Idofuranose" <i>Carbo. Res.</i> 127:149-153 (1984)		
	C45	Medakovic et al. "An Efficient Synthesis of Methyl 1,2,3,4-tetra-O-acetyl- β -L-Idopyranuronate" <i>Carbo. Res.</i> 253:299-300 (1994)		
	C46	Dromowicz et al. "A Convenient Synthesis of D-Idose" <i>Carbo. Res.</i> 308:169-171 (1998)		
	C47	Hinou et al. "Novel Synthesis of L-Iduronic Acid Using Trehalose as the Disaccharide Starting Material" <i>Tetrahedron Lett.</i> 40:1501-1504 (1999)		
	C48	Adinolfi et al. "Intramolecular Tishchenko Reactions of Protected Hexos-5-Uloses: a Novel and Efficient Synthesis of L-Idose and L-Altrose" <i>Synlett</i> 3:336-338 (1999)		
	C49	Ojeda et al. "A New Route to L-Iduronate Building-blocks for the Synthesis of Heparin-like Oligosaccharides" <i>Synlett</i> 8:1316-1318 (1999)		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

04 MAR 2005

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">O I P E 10 REED P.O. #10</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>MAR 04 2005 Date Submitted: March 2, 2005</p> <p>(use as many sheets as necessary)</p> <p>PATENT & TRADEMARK OFFICE Sheets DELETED</p>			<p style="text-align: center;">Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>10/518,177</td> </tr> <tr> <td>Int'l Filing Date</td> <td>6/18/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>David BONNAFFE</td> </tr> <tr> <td>Group Art Unit</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Examiner Name</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>355901-0104</td> </tr> </table>			Application Number	10/518,177	Int'l Filing Date	6/18/2003	First Named Inventor	David BONNAFFE	Group Art Unit	Not Yet Assigned	Examiner Name	Not Yet Assigned	Attorney Docket Number	355901-0104
Application Number	10/518,177																
Int'l Filing Date	6/18/2003																
First Named Inventor	David BONNAFFE																
Group Art Unit	Not Yet Assigned																
Examiner Name	Not Yet Assigned																
Attorney Docket Number	355901-0104																
		5	of	5													

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C50	Takahashi et al. "A Novel and Practical Synthesis of L-Hexoses from D-Glycono-1,5-Lactones" <i>J. Am. Chem. Soc.</i> 122:2995-3000 (2000)	
	C51	Horton et al. "Ethynylation of 1,2-O-Isopropylidene- α -D-xylo-Pentadialdose derivatives. A Synthetic Route to Uronic Acids" <i>Carbo. Res.</i> 14:159-171 (1970)	
	C52	Danishefsky et al. "On the Communication of Chirality from Furanose and Pyranose Rings to Monosaccharide Side Chains: Anomalous Results in the Glucose Series" <i>Tetrahedron</i> 42(11):2809-2819 (1986)	
	C53	Vasella et al. "194. Convenient Synthesis of 2-Azido-2-deoxy-aldooses by Diazo Transfer" <i>Helvetica Chemica Acta.</i> 74:2073-2077 (1991)	
	C54	Alper et al. "Metal Catalyzed Diazo transfer for the Synthesis of Azides from Amines" <i>Tetrahedron Lett.</i> 37(34):6029-6032 (1996)	
	C55	Tabeau et al. "Oligosaccharides Corresponding to the Regular Sequence of Heparin: Chemical Synthesis and Interaction with FGF-1" <i>Bioorg. & Medic. Chem.</i> 7:2003-2012 (1999)	
	C56	Oltvoort et al. "Use of the Cationic Iridium Complex 1,5-Cyclooctadiene-bis[methyldiphenylphosphine]-iridium Hexafluorophosphate in Carbohydrate Chemistry: Smooth Isomerization of Allyl Ethers to 1-Propenyl Esters" <i>Synthesis</i> 305-308 (1981)	
	C57	Dianzani F. "Interferon Treatments: How to Use an Endogenous System as a Therapeutic Agent" <i>J. of Interferon Res.</i> Special Issue May 1992, pp 109-118	
	C58	Horton et al. "Preparation of Derivatives of L-Idose and L-Iduronic Acid from 1,2-O-Isopropylidene- α -D-Glucofuranose by Way of Acetylnic Intermediates" <i>Carbo. Res.</i> 58:89-108 (1977)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.